Patients with metastatic disease and MYCN amplification who received standard chemotherapy, surgery, local radiotherapy, and autologous stem cell transplantation were randomized to receive isotretinoin alone or in combination with dinutuximab. This evidence concerns the gene MYCN and metastatic neoplasm.